PepTite(TM) Coating is an Arg-Gly-Asp (RGD)-containing synthetic peptide that has been developed at Telios Pharmaceuticals, Inc. to coat materials used in medical implants and modify their surfaces in a way to promote cell attachment. In vivo studies have indicated that implants modified with PepTite(TM) Coating demonstrate enhanced tissue integration and reduced inflammation and fibrous encapsulation. This proposal is designed to characterize the ability of Peptite(TM) Coating to enhance the hemocompatability of biomaterials commonly used to construct synthetic vascular grafts. Dacron(R) polyester, Polyurethane, ePTFE and silicone will be tested. The mechanism of cell attachment and behavior of platelet and endothelial cells will be examined on surfaces having optimal modification with Peptite(TM) Coating. In addition, using a constructed parallel platelet flow chamber, the interaction of these cells with a coated surface, particularly with respect to platelet activation, will be examined under flow conditions. Finally, a radiolabelled peptide will be synthesized and the stability of PepTite(TM) Coating will be measured under similar flow conditions. The data from this study will be used to support more in-depth studies on the behavior of implanted vascular grafts modified with PepTite(TM) Coating.Proposed commercial application:Modification of blood-contacting biomaterials with RGD peptides will increase their hemocompatability. This would, in theory, increase the patency of artificial vascular grafts. In turn, the clinical consequence will be to reduce the risk for patients and, therefore, decrease the cost to patients and the healthcare system.National Institute of Heart, Lung, and Blood Institute (NHLBI)
